IP Library Granted Patent US 7,786,299
Granted Patent B2
US 7,786,299 · App. 11/219,945 · Granted Aug 31, 2010

Methods for treating diseases or conditions using dihydropteridinone compounds

Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,786,299
App. No.
11/219,945
Granted
Aug 31, 2010
Kind
B2
Abstract

Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R 1 -R 5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

Claims (257)

1. A Compound selected from the group consisting of the compounds of formula (I) as shown in the following Table

Config.

Example

R 1

R 2

R 1 or R 2

 27

H

R

 44

H

R

 55

H

R

 58

H

R

102

H

R

103

H

R

105

H

R

110

H

R

115

H

R

133

H

R

134

H

R

234

H

R

240

H

R

Example

R 3

R 4

L n —R m 5

 27

 44

H

 55

 58

102

103

105

110

115

133

134

234

240

or a pharmacologically acceptable acid addition salt thereof,

wherein the abbreviations X1, X2, X3, X4 and X5 used in the Table in each case denote a link to a position in the general formula shown under the Table instead of the corresponding groups R1, R2, R3, R4 and L-R5.

2. The compound according to claim 1 wherein the compound is

Ex-

Config.

am-

R 1

ple

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

27

H

R

or a pharmacologically acceptable acid addition salt thereof.

3. The compound according to claim 1 wherein the compound is

Config. R 1

Example

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

44

H

R

H

or a pharmacologically acceptable acid addition salt thereof.

4. The compound according to claim 1 wherein the compound is

Ex-

Config.

am-

R 1

ple

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

55

H

R

or a pharmacologically acceptable acid addition salt thereof.

5. The compound according to claim 1 wherein the compound is

Ex-

Config.

am-

R 1

ple

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

58

H

R

or a pharmacologically acceptable acid addition salt thereof.

6. The compound according to claim 1 wherein the compound is

Config. R 1

Example

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

102

H

R

or a pharmacologically acceptable acid addition salt thereof.

7. The compound according to claim 1 wherein the compound is

Ex-

Config.

am-

R 1

ample

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

103

H

R

or a pharmacologically acceptable acid addition salt thereof.

8. The compound according to claim 1 wherein the compound is

Ex-

Config. R 1

ample

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

105

H

R

or a pharmacologically acceptable acid addition salt thereof.

9. The compound according to claim 1 wherein the compound is

Ex-

Config.

am-

R 1

ample

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

110

H

R

or a pharmacologically acceptable acid addition salt thereof.

10. The compound according to claim 1 wherein the compound is

Config. R 1

Example

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

115

H

R

or a pharmacologically acceptable acid addition salt thereof.

11. The compound according to claim 1 wherein the compound is

Ex-

Config.

am-

R 1

ple

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

133

H

R

or a pharmacologically acceptable acid addition salt thereof.

12. The compound according to claim 1 wherein the compound is

Config. R 1

Example

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

134

H

R

or a pharmacologically acceptable acid addition salt thereof.

13. The compound according to claim 1 wherein the compound is

Config. R 1

Example

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

234

H

R

or a pharmacologically acceptable acid addition salt thereof.

14. The compound according to claim 1 wherein the compound is

Ex-

Config.

am-

R 1

ple

R 1

R 2

or R 2

R 3

R 4

L n —R 5 m

240

H

R

or a pharmacologically acceptable acid addition salt thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 21, 2020
From: BOEHRINGER INGELHEIM PHARMA GMBH
To: ONCOHEROES BIOSCIENCES INC.
Reel/Frame 052722/0909 →
Continuity (3)
Continuation 1090380700 · Jul 30, 2004
Continuation 1037487600 · Feb 26, 2003
Related Publication 20060025411A1 · Feb 2, 2006